The estimated Net Worth of Eli Samaha is at least 77 百万$ dollars as of 7 August 2024. Eli Samaha owns over 999,800 units of Theravance Biopharma Inc stock worth over 77,040,315$ and over the last 2 years Eli sold TBPH stock worth over 0$.
Sign up
Eli Samaha TBPH stock SEC Form 4 insiders trading
Eli has made over 7 trades of the Theravance Biopharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Eli bought 999,800 units of TBPH stock worth 7,798,440$ on 7 August 2024.
The largest trade Eli's ever made was buying 2,633,000 units of Theravance Biopharma Inc stock on 28 December 2022 worth over 15,666,350$. On average, Eli trades about 759,667 units every 120 days since 2022. As of 7 August 2024 Eli still owns at least 9,511,150 units of Theravance Biopharma Inc stock.
You can see the complete history of Eli Samaha stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Eli Samaha's mailing address?
Eli's mailing address filed with the SEC is 150 EAST 58TH ST, STE 1403, NEW YORK, NY, 10155.
Insiders trading at Theravance Biopharma Inc
Over the last 10 years, insiders at Theravance Biopharma Inc have traded over 11,619,559$ worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth 29,986,832,769,275$ . The most active insiders traders include Plc Gsk、Inc. Innoviva,、Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of 448,635$. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth 7,798,440$.
What does Theravance Biopharma Inc do?
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
What does Theravance Biopharma Inc's logo look like?
Complete history of Eli Samaha stock trades at PFSWEB Inc、Theravance Biopharma Inc
Theravance Biopharma Inc executives and stock owners
Theravance Biopharma Inc executives and other stock owners filed with the SEC include:
-
Rick Winningham,
Chairman of the Board, Chief Executive Officer -
Andrew Hindman,
Chief Financial Officer, Senior Vice President -
Bradford Shafer,
Executive Vice President, General Counsel, Secretary -
Brett Haumann,
Senior Vice President, Clinical Development and Chief Medical Officer -
Frank Pasqualone,
Senior Vice President and Chief Commercial Operations Officer -
Philip Worboys,
Senior Vice President - Research and Translational Science -
Rick E. Winningham M.B.A.,
Chairman & CEO -
Andrew Asa Hindman,
Sr. VP & CFO -
Bradford J. Shafer,
Exec. VP, Gen. Counsel & Sec. -
Andrew Asa Hindman M.B.A,
Sr. VP & CFO -
Rhonda F. Farnum,
Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs -
William Young,
Lead Independent Director -
Burton Malkiel,
Independent Director -
Donal O'Connor,
Independent Director -
Dean Mitchell,
Independent Director -
Susan Molineaux,
Independent Director -
Eran Broshy,
Independent Director -
Laurie Alsup,
Independent Director -
George Whitesides,
Independent Director -
Robert Gunderson,
Director -
Deepika Pakianathan,
Independent Director -
Vijay Sabesan,
Senior Vice President - Technical Operations -
Kenneth Pitzer,
Senior Vice President - Product Strategy and Commercial Planning -
Ann Brady,
President - Theravance Biopharma Ireland Limited -
Dr. Ann B. Brady Ph.D.,
Pres of Theravance Biopharma Ireland Limited -
Dr. Richard A. Graham Ph.D.,
Sr. VP of Devel. -
Daniel Long,
Head of Medicinal Chemistry -
Dr. Kenneth R. Pitzer,
Sr. VP of Product Strategy & Commercial Planning -
Dr. Phillip D. Worboys,
Sr. VP of Research & Translational Science -
Dennis O. Driver,
Sr. VP of HR, Organizational and Leadership Devel. -
Gail B. Cohen,
VP of Corp. Communications & Investor Relations -
Jeremy T Grant,
-
Renee D Gala,
VP-Finance -
Peter S Ringrose,
Director -
Junning Lee,
Sr. VP, Technical Operations -
Sharathchandra S Hegde,
SVP, Research -
Henrietta Fore,
Director -
Shehnaaz Suliman,
SVP, Corp Dev & Strategy -
Jeffrey David Jonker,
Senior VP, Corp. & Bus. Dev. -
Michael G Atieh,
Director -
Leonard M Blum,
Sr VP, Chief Comm. Officer -
Inc. Innoviva,,
10% owner -
Mathai Mammen,
SVP, Research & Early Clin Dev -
Rhonda Farnum,
SVP, COMM & MEDICAL AFFAIRS -
Richard A Graham,
SVP, RESEARCH & DEVELOPMENT -
Plc Gsk,
-
Aziz Sawaf,
SVP & CHIEF FINANCIAL OFFICER -
Brett A. Grimaud,
SVP, GEN COUNSEL AND SECRETARY -
Susannah Gray,
-
Aine Miller,
SVP, DEV & HEAD OF IRE OFFICE -
Eli Samaha,
10% owner